spacer
home > ebr > Summer 2003
PUBLICATIONS

European Biopharmaceutical Review

ebr
Summer 2003
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott gives us a brief synopsis of the range and content of this issue  
view
bullet
STRATEGY AND FINANCE
Dr Helen Abbott, Senior Consultant at Technomark, reviews Ernst and Young's European Biotechnology Report 2003, Endurance: European Biotech - Surviving the Storm  
view
Morten Soegaard, Research Analyst at Frost & Sullivan, identifies routes to Maximising Return on Investment with R&D Portfolio Management  
view
Pharmaceutical companies are finding it increasingly difficult to boost the output of new drugs. In Biotechnology: Breathing New Life into Drug Development, Faiz Kermani, Budgets, Proposals and Marketing Executive, and Pietro Bonacossa, Marketing Executive, at Chiltern International Inc, provide some potential answers  
view
Science and Innovation
The era of 'super vaccines' could be just around the corner, mitigating everything from herpes, to cancers and even AIDS. Biotech industry guru G Steven Burrill, CEO of Burrill & Company, leads us through The Future of Vaccines  
view
In Giving Vaccines the Boost They Need, we look at the innovations behind today's vaccine industry with Dr Deirdre Gillespie, President and Chief Executive Officer at Oxxon PharmaccinesTM Ltd  
view
More people in their 60s and beyond are falling victim to conditions such as Alzheimer's, Parkinson's and stroke. Dr Itzchak Angel, Vice President Research and Development at D-Pharm Ltd, examines the battle against Losing Our Minds - What the Future Holds for the Treatment of Neurodegenerative Disorders  
view
As the mortality rate for SARS reaches some 15 per cent, we consider Fighting SARS in the Post-Genomic Era with Professor Yike Guo, Technical Director of the Parallel Computing Centre and Head of the Data Mining Group of Imperial College, and Dr Wayne He, Director of SCBIT-IBM-InforSense Joint Laboratory of the Shanghai Center for Bioinformation Technology (SCBIT)  
view
Meanwhile, Dr George Rowland, Chairman and Co-Founder of ZinCare International Ltd investigates The Potential of Zinc Ions for Prophylaxis and Treatment of Severe Acute Respiratory Syndrome (SARS)  
view
BioDevelopment
Dr Michael I Ugwoke, Scientist Formulation Development/Project Leader, and Professor Daan JA Crommelin, Scientific Director at OctoPlus Development BV, explain Biopharmaceuticals: A Special Breed of Drugs  
view
Dr Mark Millichip, HPLC Applications Technical Support Specialist at Polymer Laboratories Ltd, asks Are 'Polymerics' Coming of Age?  
view
Perspectives in Preclinical Development are offered by Thomas Allen, Director of Allen Preclinical Consultants GmbH  
view
With demand increasing, Dr Stephen Little, CEO of DxS Ltd, examines How to Include Genetic Analysis in Clinical Trials  
view
What happens when breakthrough biotech products are so successful they overwhelm manufacturing capacity? Geoff Tomlinson, Principal and Hannes Kunz, Director of PRTM, look at Managing your Way Out of the Success Trap  
view
Didn't attend? Read the review - SMi Conference London March 2003, Biologics: Overcoming the Challenges of Development and Manufacture  
view
bullet
Legal, Regulatory and Public Policy
In The Cognitive Assessment of Herbal Products - Are the Effects Imagined or Real? Tamsin Manktelow, Scientific Development Manager, and Andrea Zangara, Research Associate, at Cognitive Drug Research Ltd, guide us through new EU legislation and its impact on traditional herbal remedies  
view
Sean Flanagan, Commercial Director at Kryotrans Ltd, and Adrian Shaw, Partner at Ikon Associates, outline Cold Chain: Risk, Regulatory Compliance and Operational Performance  
view
Audrey Bottomley, David Myers and Chris Willoughby of the Reproductive Studies Group at Huntingdon Life Sciences, ask Preclinical Juvenile Toxicity Studies: Will it be Safe for Children?  
view
bullet
Drug Discovery
In the race to bring new biotech derived products to market, researchers face many obstacles along the road from discovery to commercial success. Dr Fiona M Greer, Director, Biochemical Services at M-Scan Ltd, answers some queries about the use of mass spectrometry in Biopharmaceutical Characterisation - Considering Key Questions  
view
Ralf Moritz, Application Chemist at Agilent Technologies and Nicola O'Reilly at Cancer Research UK, look at Mass-Based Fraction Collection of Crude Synthetic Peptides in Analytical and Preparative Scale for cancer treatment  
view
In Making the Remarkable Routine, Professor Alan Marshall, National High Magnetic Field Laboratory at Florida State University, USA and Dr Alan Street, Oxford Instruments Superconductivity, at Oxford Instruments, UK, consider high-field FT-ICR MS - a powerful technique for composition and structural analysis  
view
As the advent of proteomics switches the emphasis from genes to proteins, increased scientific attention is being paid to techniques that produce detailed information on human proteins. Dr Stefan Lofus, Vice President and Chief Scientific Officer at Biacore AB, evaluates one such technique in SPR-MS in Functional Proteomics  
view
Christophe Fraudeau, Marketing Manager at Jouan Robotics, charts Trends in Laboratory Robotics in the Biopharmaceutical Industry  
view
bullet
IP AND TECHNOLOGY TRANSFER
Nika V Ketis, Lawyer at Bennett Jones, examines The Baker Case and Eight-Part Test for Considering Disclosure by Prior Use or Sale  
view
Are Patents the Beating Heart of your Boardroom? Ian Harvey, Chief Executive Officer of BTG plc and Chairman of the Government's Intellectual Property Advisory Committee, explains why they should be  
view
bullet
Preview
As the official publication for CORDIA - EuropaBio Convention 2003, we bring you all the news and views on Europe's first comprehensive life science convention to be held this December  
view
bullet
BIOINFORMATICS
Geoff Parker, Commercial Director at Scimcon, balances biological research against computer-based research in The Biotech Juggling Act  
view
Collaborative drug discovery decisions from diverse locations in real-time? Dan Stevens, Marketing Manager, Life and Chemical Sciences at SGI, welcomes us to Visualisation in Drug Discovery: The Way of the Future  
view
bullet
REGIONAL FOCUS: BELGIUM
Rudy Aernoudt, Deputy Head of Cabinet of the Walloon Ministry for Economy and Research, brings us The Blossoming of Biotechnology in Wallonia  
view
bullet
REGIONAL FOCUS: UK
Jeanette Walker, Business Development Director at ERBI, sheds light on Cambridge, England - Europe's Low Risk Biotech Location  
view
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

CPhI India Report identifies two-tier manufacturing market and predicts increased acquisitions


More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

Industry Events

7th annual Orphan Drugs and Rare Diseases UK

18-19 October 2017, Holiday Inn Kensington Forum, London

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement